Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factorsLisa Bodei, Irvin M. Modlin, Dik J. Kwekkeboom et al.|European Journal of Nuclear Medicine and Molecular Imaging|2014Cited by 465
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.Dik J. Kwekkeboom, Eric P. Krenning, Jan Mueller‐Brand et al.|PubMed|2005Cited by 375
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin AnaloguesRodney J. Hicks, Dik J. Kwekkeboom, Eric P. Krenning et al.|Neuroendocrinology|2017Cited by 331
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future ProspectsSonya Park, Erik Mittra, Ashwin Singh Parihar et al.|Journal of Nuclear Medicine|2021Cited by 71